The edge-to-edge approach with MitraClip has been established as a valid strategy for patients who experience severe symptomatic mitral regurgitation (MI) with high risk for surgery, currently with a IIa indication. MI complicated by cardiogenic shock, which results in a high risk for conventional valve surgery, is a particularly complex scenario. In such a case,<a href="https://solaci.org/en/2024/02/26/edge-to-edge-repair-in-cardiogenic-shock/" title="Read more" >...</a>
Use of Intravascular Lithotripsy vs. Rotational Atherectomy for Severely Calcified Coronary Lesions
Severely calcified coronary stenosis poses a significant challenge for coronary angioplasty procedures. Modifying plaque before stenting is crucial to a successful intervention, since it will prevent the sub expansion associated to worse clinical outcomes at followup. The tools employed to assess complex lesions include specialized balloons such as cutting, scoring, or high pressure balloons, as<a href="https://solaci.org/en/2024/01/22/use-of-intravascular-lithotripsy-vs-rotational-atherectomy-for-severely-calcified-coronary-lesions/" title="Read more" >...</a>
Long-term Results of Coronary Bifurcation Lesion Treatment in Diabetic Patients
The effects of diabetes on patients with coronary artery disease are well-known, and their outcomes after angioplasty are less favorable, with a higher rate of restenosis, recurrent acute myocardial infarction, and stent thrombosis. Despite advances in drug-eluting stents and procedural techniques, the treatment of coronary bifurcation lesions in diabetic patients shows less positive clinical outcomes<a href="https://solaci.org/en/2024/01/18/long-term-results-of-coronary-bifurcation-lesion-treatment-in-diabetic-patients/" title="Read more" >...</a>
Interventional Cardiology: The Most Read Articles of 2023
Discover the most read scientific articles on interventional cardiology of 2022 in our website. No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of<a href="https://solaci.org/en/2023/12/27/interventional-cardiology-the-most-read-articles-of-2023/" title="Read more" >...</a>
Revascularization vs. Deferral of Physiologically Significant Lesions in the Left Main Coronary Artery
Most randomized studies on decision-making in coronary artery disease revascularization exclude left main coronary artery disease (LMCAD), as did the ISCHEMIA Study. On the other hand, the benefits of functionally assessing lesions, proven in studies such as FAME, emphasize the importance of this tool in guiding revascularization decisions. However, there is still little understanding of<a href="https://solaci.org/en/2023/12/06/revascularization-vs-deferral-of-physiologically-significant-lesions-in-the-left-main-coronary-artery/" title="Read more" >...</a>
Optimal Duration of DAPT with Oral Anticoagulation After PCI?: 1 Month vs. 3 Months
While the benefits of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor are recognized, its primary complication is the occurrence of bleeding events, which negatively impact patient morbidity and mortality. Additionally, about 10% of patients undergoing percutaneous coronary intervention (PCI) are on oral anticoagulant therapy, which significantly increases the risk of bleeding when<a href="https://solaci.org/en/2023/11/23/optimal-duration-of-dapt-with-oral-anticoagulation-after-pci-1-month-vs-3-months/" title="Read more" >...</a>
Stentless Strategy in ACS: Perfusion and Drug Coated Balloons
The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding. However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>
Cause of Cardiac Death after TAVR at Present
Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup. In its early days, TAVR also showed benefits, but<a href="https://solaci.org/en/2023/10/11/cause-of-cardiac-death-after-tavr-at-present/" title="Read more" >...</a>
Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI
The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with high risk of acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) is based on randomized studies and current guideline recommendations. However, clopidogrel is still recommended for patients at high risk of bleeding. Several strategies have been looked<a href="https://solaci.org/en/2023/09/20/substudy-talos-ami-from-ticagrelor-to-clopidogrel-in-patients-with-high-risk-of-bleeding-and-ami/" title="Read more" >...</a>
AMI and Multivessel Disease: Can We Perform a Single Procedure?
Percutaneous coronary intervention (PCI) is considered the treatment of choice in ST-segment elevation myocardial infarction (STEMI). However, it is widely acknowledged that, in many cases, there are significant lesions in other coronary arteries. Previous randomized studies have shown that complete revascularization in a second procedure is more beneficial than intervention only in the culprit artery.<a href="https://solaci.org/en/2023/09/19/ami-and-multivessel-disease-can-we-perform-a-single-procedure/" title="Read more" >...</a>